Products for Research Use Only
RegisterLogin

Otaplimastat

CAT: 0804-HY-109097-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109097-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
CAS Number
1176758-04-5
Product Name Alternative
SP-8203
UNSPSC
12352005
Target
IGluR; MMP
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/otaplimastat.html
Purity
98.11
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(N(CCCN1C(NC2=C(C=CC=C2)C1=O)=O)CCCCNCCCN3C(NC4=C(C=CC=C4)C3=O)=O)=O
Molecular Formula
C28H34N6O5
Molecular Weight
534.61
References & Citations
[1]Noh SJ, et, al. SP-8203 shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor. Pharmacol Biochem Behav. 2011 Nov;100 (1) :73-80.|[2]Noh SJ, et, al. SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia. Pharmacol Biochem Behav. 2011 Mar;98 (1) :150-4.|[3]Kim JS, et, al. Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA) : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2020 Feb;87 (2) :233-245.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
MMP; NMDA Receptor

Alternative Products

CatalogName
BA6752-5Otaplimastat
GTR19264848-01Otaplimastat HCl

Popular Products